Assessment of Pharmacokinetic Effects of Herbal Medicines on Escitalopram
Open Access
- 1 February 2024
- journal article
- research article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 20, 151-160
Abstract
Purpose: Herbal medicines are occasionally used in combination with conventional antidepressants to mitigate various depression-associated symptoms. However, there is limited information on herb–antidepressant interactions. In this study, we investigated the pharmacokinetic (PK) effects of four herbal medicines (Gami-soyosan, Banhasasim-tang, Ojeok-san, and Bojungikgi-tang) on escitalopram, a commonly used antidepressant. Patients and Methods: In this open-label, fixed-sequence, three-period, crossover study, 18 participants were enrolled and divided into two groups. Each group received a 10 mg oral dose of escitalopram in period 1. Participants took escitalopram once daily and their assigned herbal medicines thrice a day for 7 d in periods 2 (group 1: Gami-soyosan, group 2: Ojeok-san) and 3 (group 1: Banhasasim-tang; group 2: Bojungikgi-tang). The primary endpoints were Cmax,ss and AUCtau,ss of escitalopram. Cmax,ss and AUCtau,ss in period 1 were obtained using nonparametric superposition from single-dose data. The PK endpoints were classified according to the CYP2C19 phenotype. Results: Of 18 participants, 16 completed the study. Systemic exposure to escitalopram resulted in a minor increase in the presence of each herbal medicine. The geometric mean ratios (GMRs, combination with herbal medicines/escitalopram monotherapy) and their 90% confidence intervals (CIs) for Cmax,ss and AUCtau,ss were as follows: Gamisoyosan– 1.1454 (0.9201, 1.4258) and 1.0749 (0.8084, 1.4291), Banhasasim-tang– 1.0470 (0.7779, 1.4092) and 1.0465 (0.7035, 1.5568), Ojeok-san– 1.1204 (0.8744, 1.4357) and 1.1267 (0.8466, 1.4996), and Bojungikgi-tang– 1.1264 (0.8594, 1.4762) and 1.1400 (0.8515, 1.5261), respectively. Furthermore, no significant differences in the GMRs of Cmax,ss and AUCtau,ss were observed across different CYP2C19 phenotypes in any of the groups. Conclusion: The co-administration of escitalopram with Gami-soyosan, Banhasasim-tang, Ojeok-san, or Bojungikgi-tang did not exert significant PK effects on escitalopram. These findings provide valuable insights into the safe use of herbal medicines along with escitalopram.Keywords
This publication has 41 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsClinical Pharmacology & Therapeutics, 2015
- Evaluation of metabolism-mediated herb-drug interactionsArchives of Pharmacal Research, 2011
- Escitalopram Is a Weak Inhibitor of the CYP2D6-Catalyzed O-Demethylation of (+)-Tramadol but Does Not Reduce the Hypoalgesic Effect in Experimental PainClinical Pharmacology & Therapeutics, 2009
- Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarkerEuropean Journal of Clinical Pharmacology, 2009
- Screening for inhibitory effect on nine CYP isoforms by 20 herbal medicationsJournal of Life Science, 2007
- The Clinical Pharmacokinetics of EscitalopramClinical Pharmacokinetics, 2007
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLOS Medicine, 2006
- Cognitive and neurological impairment in mood disordersPsychiatric Clinics of North America, 2004
- Herb–drug interactions: Review and assessment of report reliabilityBritish Journal of Clinical Pharmacology, 2001
- A Pharmacokinetic/Pharmacodynamic Comparison of SAAM II and PC/WinNonlin Modeling SoftwareJournal of Pharmaceutical Sciences, 1998